Influence of carnauba wax on the release profile of ibuprofen implants

Year 2022, , 45 - 56, 28.04.2022

Collins Airemwen Jude Isesele Johnbull Obarisiagbon Emmanuel Halılu Michael Uhumwangho

https://doi.org/10.54994/emujpharmsci.986291

Abstract

Pharmaceutical implants are small sterile solid masses usually cylindrical consisting of a highly potent and purified drug intended to be subcutaneously implanted beneath the skin by suitable special injector or by surgical incision for the purpose of providing the continuous release of the active medicament over a prolonged period of time. The purpose of this study was to evaluate the influence of carnauba wax on the release profile of ibuprofen implants. The implants were prepared with gelatin, hydroxypropyl methylcellulose admixture (80:20) and varying amount of carnauba wax (2.5%, 5%, 7.5%) using the solvent casting technique. Another batch of the implant was formulated without the incorporation of carnauba wax. Glycerin was used as the plasticizing agent. The physicochemical properties and the release kinetics of the implants were evaluated. The implant pellets had a similar appearance with minimal batch to batch variation. The mean diameter/thickness of the implants ranged from 2.46±0.10-2.86±0.03 mm, the percentage drug content was ≤96.92±0.12% and the swelling index values were between 2.68±0.01 – 4.87±0.01%. The rate of drug release from the ibuprofen implants was significantly affected by the incorporation of carnauba wax. The higher the amount of carnauba wax incorporated in the formulation, the more retarded the rate of drug release. This can be exploited in the formulation of sustained release ibuprofen implants for the management of chronic diseases such as arthritis.

Keywords

Carnauba wax, ibuprofen, subcutaneous, implant.

Supporting Institution

University of Benin, Benin-City, Nigeria

Project Number

1

Thanks

Thank you

References

• Alissa R, Sakka S, Oliver R (2009). Influence of Ibuprofen on bone healing around dental implants: a randomized double blind placebo controlled clinical study. Eur J Oral Implant 2(3):185-199.
• British Pharmacopoeia (2012). London, UK: Her Majesty’s Stationery Office: A234.
• Desai KGH, Mallery SR, Schwendeman SP (2008). Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly (lactide-co-glycolide) implants. Eur J Pharm 70(1): 187-198.
• Garcia JT, Jesus DM, Mungia O, Llabres M, Farina JB (2002). Biodegradable laminar implants for sustained release of recombinant human growth hormone. J Biomaterials 23(4): 4759-4764.
• Gisele R, Da Silva L, Sílvia LF, Rubens CS, Rodrigo J, Armando-da-Silva CJ (2010). Implants as drug delivery devices for the treatment of eye diseases. Brazilian J Pharm Sci 46(3): 585-595.
• Grosser T, Ricciotti E and FitzGerald GA (2017). The Cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs, A Review. British J Pharm, 172(9): 2152- 2158.
• Higuchi T (1963). Mechanism of sustained action medication. Theoretical analysis of rate release of solid drugs dispersed in solid matrices. J. Pharm. Sci 52: 1145-1149.
• Isesele JE, Airemwen CO, Uchendu AP, Asemwota IO, Obarisiagbon AJ and Uhumwangho MU (2021).
• Formulation and in vivo studies of ibuprofen biodegradable implants. Eur J Pharm and Med Res 8(7), 58-65.
• Kanzaria R, Kapadia Y, Lalji B, Desai TR (2012). Implant - controlled release medicated formulation. Int J Pharm and Chem Sci 1(1):59- 66.
• Korsemeyer RW, Gurny R, Doelker EM, Buri P and Peppas NA (1983). Mechanism of solute release from porous hydrophilic polymers, Int J Pharm 15: 25-35.
• Koster R, Anderson M, De Beer EJ (1959). Acetic acid-induced analgesic screening. Federation proceedings 18:412-417. Michael NP, Yogeshvar NK, Michael H and Michael SR. Transdermal patches: history, development and pharmacology. British J Pharm 172(9): 2179- 2190.
• Mohammed MI, Sanjeev E, Shanti S (2012). Design and evaluation of subcutaneous implantable drug delivery system of tramadol using natural biodegradable polymer. Annals Phytomed 2:30-38.
• Negrin, CM, Delgado A, Llabres M, Evora C (2004). Methadone implants for methadone maintenance treatment, In vitro and in vivo animal studies. J Con Release 95: 413-421.
• Oalta R, Grewal Y, Batth S, Singh A (2015). A Survey of analgesic and anti-inflammatory drug prescription for oral implant surgery. Int J Plastic and Aesthetic Res 2: 51-55.
• Onishi HM, Takahashi N and Machinda Y (2005). PLGA implant tablet of ketoprofen: comparison of in vitro and in vivo releases. Biol Pharm Bull 28(10): 2011-2015.
• Onyechi JO and Okafo SE (2016). Evaluation of carnauba wax in sustained release diclofenac sodium tablet formulation J Chem. Pharm. Res 8(3):714-721.
• Purushotham RK, Jaybhaye SI, Ravindra K, Bhandari A, Pratima S (2010). Designing of Diclofenac Sodium Biodegradable Drug Implant for Speedy Fracture Healing. J Chem Pharm Res 3(1) 330-337.
• Rajgor N, Pale M and Bhaskar VH (2011). Implantable Drug Delivery Systems, An Overview Systematic Rev Pharm 2(2): 91-95.
• Rao KP, Jaybhaye SJ, Ravindra K, Anil B, Pratima S (2010). Designing of Diclofenac sodium Biodegradable Drug Implant for Speedy Fracture Healing. J Chem Pharm Res 3(1) :330-337.
• Satish CS (2017). Formulation and Evaluation of a Chitosan-PVA-gellan insulin implant, Int J App Pharm 9(3): 37-41.
• Tian H, Tang Z, Zhuang X, Chen X, Jing X (2012). Biodegradable synthetic polymers: preparation, functionalization and biomedical application. Prog. Poly Sci. 37: 237- 280.
• Wang CK, Wang WY, Meyer RF, Liang Y, Winey KI, Siegel SJ (2010). A raid method for creating drug implants: Translating laboratory-based methods into a scalable manufacturing process. J Biomed Mater Res 5(2): 562-572.